NEW YEAR OFFER! | 65% OFF YOUR FIRST ORDER
AboutBlood TestFor Employers
Sign up

Healthier for longer with responsible care™

Sign up

The obesity epidemic

By 2030 nearly 3 billion adults will be overweight or obese worldwide.¹ eMed’s mission is to combat today’s obesity epidemic with responsible access to proven GLP-1 treatment and long term, holistic support.

We offer branded, FDA-approved GLP-1 medications paired with a structured program designed to be clinically sound, affordable, and sustainable.

Sign up

1 World Obesity Atlas 2025.
‍

Qualifying eligible population
Clinical prescribing
Transparent
sourcing
Supportive clinical care

Our commitment
to clinical safety

In a market flooded with unregulated counterfeits and inconsistent sourcing, we remain committed to a higher standard.
‍
Understanding where your health stands at the start allows us to measure change with accuracy and intention. Every patient begins with a blood test to establish a personal health profile. This is not meant as a barrier but as the foundation for responsible prescribing and long-term individualized progress tracking.

Sign up

The formula for lasting transformation

We believe the true differentiator in outcomes is adherence. GLP-1 medications generate powerful results when taken consistently over time, and consistency requires support.

Our program is designed for real-life use with access to clinicians, digital health communication, and structured touch points that reduce friction and increase follow-through.

Sign up

2 American Diabetes Association, Standards of Care in Diabetes 2024.
‍

Groundbreaking medication

What are GLP-1s?

Semaglutide and tirzepatide medications mimic a natural peptide your body already produces, called GLP-1 (glucagon-like peptide-1). This peptide helps regulate appetite, manage blood sugar, and slow digestion.3

By activating these same pathways, medications like Wegovy® and Zepbound® help you feel full sooner, stay full longer, and eat less without feeling restricted.

Wegovy® Pill important safety information

Zepbound® important safety information

Ozempic®* important safety information

Wegovy® important safety information

3 NEJM, Semaglutide STEP 1 Trial, 2021.

* Ozempic has not been reviewed or approved by the FDA for weight-loss use. Any prescription decisions are made independently by licensed clinicians based on individual clinical evaluation.

What to expect

At-home screening

Fill out your medical profile and be guided through a simple, at-home blood collection.

Check your eligibility

A licensed clinician will review your medical profile and lab results.

Receive GLP-1 medication

If eligible, your GLP-1 prescription will be sent to your door.

Weekly check-ins

Track your progress with a quick, 60-second check-in through the app each week.

Sign up

Solutions
About
Blood Test
Press
Careers
Resources
FAQ
Connect
© 2025 eMed® All rights reserved. The products of eMed are protected by patents. Privacy Policy | Terms of Use | Notice of Privacy Practices | Biometric Data Privacy Policy  | Consumer Health Data Privacy Notice | Florida Patients | UK Operations  
Wegovy ® and Ozempic ® are registered trademarks of Novo Nordisk A/S.
Zepbound ® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.
All other trademarks, registered or unregistered, are the property of their respective owners.
Prescriptions for medication subject to a consultation with a licensed clinician. Not all persons may be eligible or qualify to receive a prescribed treatment.
Verify Approval for www.emed.com